Windtree Therapeutics, Inc.
WINT
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.12M | 7.91M | 8.24M | 8.42M | 8.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.74M | 24.20M | 24.52M | 25.36M | 25.31M |
| Operating Income | -16.74M | -24.20M | -24.52M | -25.36M | -25.31M |
| Income Before Tax | -14.98M | -16.17M | -1.79M | -9.64M | -11.07M |
| Income Tax Expenses | -317.00K | -120.00K | -6.00K | 71.00K | 311.00K |
| Earnings from Continuing Operations | -14.66 | -16.05 | -1.79 | -9.71 | -11.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.66M | -16.05M | -1.79M | -9.71M | -11.38M |
| EBIT | -16.74M | -24.20M | -24.52M | -25.36M | -25.31M |
| EBITDA | -16.63M | -24.10M | -24.41M | -25.24M | -25.23M |
| EPS Basic | -218.68 | -1.26K | -1.26K | -1.26K | -1.05K |
| Normalized Basic EPS | -95.24 | -736.81 | -734.50 | -750.75 | -642.94 |
| EPS Diluted | -218.68 | -1.26K | -1.26K | -1.26K | -1.05K |
| Normalized Diluted EPS | -95.24 | -736.81 | -734.50 | -750.75 | -642.94 |
| Average Basic Shares Outstanding | 6.16M | 1.29M | 201.00K | 29.20K | 11.50K |
| Average Diluted Shares Outstanding | 6.16M | 1.29M | 201.00K | 29.20K | 11.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -5.10% | -4.65% | -36.77% | -3.57% | -- |